本文へスキップ
Likelier

行動 vs. 不行動:各選択の数値

積極的な長寿介入(サプリ、断食、バイオハッキング)を追求する 対 標準的な老化を受け入れる

行動した場合

積極的に長寿を追求する(断食、サプリ、バイオハッキング)

直接の測定はありません

行動しなかった場合

標準的な老化を受け入れる(バイオハッキングなし、従来の医療)

44%

少なくとも1つの数値は間接的な推定値であり、実際に測定した後悔の割合ではありません。各数値の算出方法は下に記載しています。


健康

最終確認 2026-05-30

証拠の質 4.0/5

8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。

D1 出典の検証
4/5
D2 出典の権威性と独立性
5/5
D3 後悔率の正確性
2/5
D4 出典の比較可能性
3/5
D5 ギロヴィッチ・パターン
4/5
D6 文章の質
5/5
D7 注意事項の完全性
4/5
D8 サンプルの質
5/5
平均 4.0/5
A bathroom counter divided in two: one side covered with supplement bottles and a tracking app, the other with a single glass of water and an open book.
間接データ:この決断については、少なくとも1つの数値が、後悔を直接尋ねた調査ではなく、結果、満足度、意向といった間接的な指標、または編集部による推定に基づいています。各数値の算出方法は、下の各選択肢の注記に記載しています。

行動した場合

積極的に長寿を追求する(断食、サプリ、バイオハッキング)

直接の測定はありません

この選択肢について数値を示す出典がないため、数値は表示していません。

調査されたコホート横断の成人(オランダの老化保護調査、米国の食事サプリ使用者)

横断的、表明された意欲と有病率

行動しなかった場合

標準的な老化を受け入れる(バイオハッキングなし、従来の医療)

44%

米国の成人の38%が、老化を劇的に遅らせ寿命を延ばす医療を望むだろうと述べている(Pew 2013)。これは選好の代理指標であり、標準的な老化を受け入れることの予期的な後悔等価であって、実測された後悔率ではない

米国成人、全国代表

横断的、予期的選好

各選択の数値(何を測ったかはページに明記)

関連する決断

意味的に類似する決断 — 同じ領域、異なるトレードオフ。

健康

運動習慣

各選択の数値(何を測ったかはページに明記)

健康直接

早期診断

この選択を後悔した割合

不作為が優勢

不作為の後悔が1.3倍高い

健康

DNA祖先・健康テスト vs. 受けない

各選択の数値(何を測ったかはページに明記)

健康

代替医療のみ vs. 標準腫瘍治療

各選択の数値(何を測ったかはページに明記)

健康

積極的化学療法 vs. 早期緩和ケア

行動と不作為:各選択の情報源

健康

禁煙

各選択の数値(何を測ったかはページに明記)

lifestyle

菜食主義

各選択の数値(何を測ったかはページに明記)

健康

不妊治療を追求 vs. 子なしを受け入れる

各選択の数値(何を測ったかはページに明記)

The cleanest data point on the action side comes from a 2024 Dutch survey of 178 adults in Translational Medicine of Aging (PMC11573782), which measured stated willingness to adopt longevity interventions across a familiarity gradient: 81.5% willing to take supplements, 66.3% willing to exercise as a geroprotection regimen, 29.8% willing to do intermittent fasting, 26.4% willing to take metformin off-label, and only 9.55% willing to take rapamycin. Trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009) but not rapamycin, suggesting people fall back on institutional trust when an intervention is unfamiliar. Cross-referenced against CDC NHANES data brief 561, 60.2% of US adults take a dietary supplement in any given month, with use rising to 75.9% in adults over 60. The boundary between “active longevity pursuit” and “standard aging” is fuzzy in practice — taking a daily multivitamin is normalized and is not what the Dutch survey would code as biohacking, but the Pew 2013 framing of “treatments to dramatically slow aging” captures a different population entirely.

Kraus et al.’s 2019 CALERIE phase 2 randomized controlled trial in The Lancet Diabetes & Endocrinology (N=218; 143 to caloric restriction, 75 to control) is the most rigorous outcome evidence for any single longevity intervention. After 2 years, the restriction group achieved a mean 11.9% calorie reduction (below the 25% protocol target) and showed significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (p<0.001 to p=0.012). The biomarker case for one specific active intervention is solid. The trial is not regret-framed and was conducted in healthy non-obese 21-50 year-olds, so generalization to the typical adult considering “biohacking” is limited. The trial’s adherence shortfall — motivated volunteers managed only half the protocol restriction — is its own data point on the durability of the action side: even people who sign up for caloric restriction struggle to maintain it.

The inaction side is anchored on Pew Research’s 2013 nationally representative survey of 2,012 US adults: asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% said no, while the complementary 44% said they would want such treatments; 69% prefer a life span of 79-100 years; only 9% would want to live past 100. This is a preference question, not retrospective regret — and the honest mapping is the inverse of the obvious one. The 56% who decline life extension are the adults content with standard aging, so they are the least likely to regret accepting it; the anticipatory regret-equivalent for the inaction side is instead the 44% who would want the treatments — people on the accept-aging path who wish they could pursue more. We use that 44% as the inaction-side proxy. Adults answering at age 45 may feel differently at 75. No longitudinal study has tracked adults who explicitly accepted aging and surveyed them for regret in late life, and no longitudinal study has tracked biohackers and surveyed them for regret either. We publish this entry with both rates as indirect measures because the evidence asymmetry is genuine: cardiometabolic biomarkers are well-measured, lived regret is not. The precise magnitudes of retrospective regret on either side remain unmeasured in the published literature.

出典: 行動

根拠台帳

以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。

2/2 件の出典が引用元と一字一句一致することを独立して検証済み

  1. [1] Frontiers in Aging / PMC — Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use 検証済み
    Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use
    統計値
    In a Dutch survey (N=178), willingness to adopt longevity interventions: exercise 66.3%, supplements 81.5%, intermittent fasting 29.8%, metformin 26.4%, rapamycin 9.55%; trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009)
    抜粋
    “A questionnaire was used to assess the attitudes of a sample of the Dutch population by way of both convenience and snowball sampling (final N = 178). … Relatively high social acceptance, indicated by respondents stating they certainly or probably would adopt the measure, of both exercise (66.3%; 95% CI 59.0–72.9) and supplements (81.5%; 95% CI 75.0–86.6) is observed. The intermittent fasting schedule is less supported (29.8%; 95% CI 23.5–37.0), as is metformin (26.4%; 95% CI 20.4–33.4). … Rapamycin use was the least accepted geroprotective strategy (9.55%; 95% CI 5.99–14.9). … Trust in medical institutions correlated significantly with the willingness to start metformin use (r = .194, p = .009) ”
    出典データ
    2024-11-19
    アクセス日
    2026-11-16
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Convenience and snowball sample of 178 Dutch adults, recruited December 2022 through March 2023. The 81.5%/29.8%/9.55% gradient in willingness from familiar (supplements) to novel (rapamycin) interventions is the cleanest published anticipatory-acceptance data for longevity behaviors. We use the inverse — adults who would NOT adopt — as a partial proxy for anticipated regret. No action-side regret figure is shown: the stated willingness to start (~80% for supplements) set against observed long-term adherence in the published supplement literature (typically 50-60%, see Bailey et al. 2013 NHANES analyses cited in secondary literature) is an anticipatory and adherence signal, not a measured regret rate. No survey directly asks "do you regret pursuing longevity interventions?"
  2. [2] The Lancet Diabetes & Endocrinology (Kraus et al.) — 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial 検証済み
    2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
    統計値
    In the CALERIE 2 RCT (N=218 randomized, 143 to caloric restriction, 75 to control), the intervention group achieved a mean 11.9% calorie reduction vs 0.8% control, with significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (all p<0.001 to p=0.012)
    抜粋
    “218 were randomly assigned to and started a 25% calorie restriction diet (n=143, 66%) or an ad libitum control diet (n=75, 34%). … Individuals in the calorie restriction group achieved a mean reduction in calorie intake of 11·9% (SE 0·7; from 2467 kcal to 2170 kcal) versus 0·8% (1·0) in the control group … Calorie restriction caused a persistent and significant reduction from baseline to 2 years of all measured conventional cardiometabolic risk factors, including change scores for LDL-cholesterol (p<0·0001), total cholesterol to HDL-cholesterol ratio (p<0·0001), and systolic (p<0·0011) and diastolic (p<0·0001) blood pressure. In addition, calorie restriction resulted in a significant improvement at 2 years in C-reactive protein (p=0·012), insulin sensitivity index (p<0·0001), and metabolic syndrome score (p<0·0001) relative to control. ”
    出典データ
    2019-07-11
    アクセス日
    2026-11-16
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Kraus et al. (2019), Lancet Diabetes & Endocrinology (PMID 31303390). CALERIE phase 2 RCT in healthy 21-50 year-old non-obese adults. Demonstrates that sustained 11.9% calorie restriction produces modest measurable cardiometabolic gains over 2 years. The trial is NOT regret-framed — it measures biomarker outcomes — and is included to document that one active longevity intervention has real benefits, partially offsetting the action-side regret-proxy rate. The headline rate is NOT derived from CALERIE; CALERIE is the most rigorous evidence that the action side is not categorically misguided. Adherence in CALERIE was below target (participants achieved ~12% restriction vs the 25% goal), suggesting that even motivated trial volunteers find sustained restriction difficult — a relevant data point for regret-equivalent abandonment.

出典: 不作為

根拠台帳

以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。

1/2 件の出典が引用元と一字一句一致することを独立して検証済み

  1. [1] Pew Research Center — Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
    Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
    統計値
    Asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% of US adults say no; the complementary 44% say they would want such treatments; 69% prefer a life span of 79 to 100 years; only 9% would choose to live more than 100 years; survey of 2,012 adults March 21-April 8, 2013
    抜粋
    “"Asked whether they, personally, would choose to undergo medical treatments to slow the aging process and live to be 120 or more, a majority of U.S. adults (56%) say 'no.' But roughly two-thirds (68%) think that most other people would. [...] Fully 69% of American adults would like to live to be 79 to 100 years old. About 14% say they would want a life span of 78 years or less, while just 9% would choose to live more than 100 years." ”
    出典データ
    2013-08-06
    アクセス日
    2026-05-30
    計算過程
    Pew Research Center, nationally representative cell and landline survey of 2,012 US adults, March 21 through April 8, 2013; margin of error +/- 2.9 percentage points. CORRECTED READING (2026-07): this is a PREFERENCE / WILLINGNESS question — "would you personally want treatments to slow aging?" — not a retrospective regret question. Pew reports 56% say "no"; the complementary 44% are read here as those who would want such treatments. People who prefer standard aging (the 56% who decline life extension) are the LEAST likely to regret accepting it, so they cannot stand in for the inaction-side regret rate. The honest indirect measure of anticipatory regret of the inaction side is the 44% who say they WOULD want life-extension treatments — i.e. adults on the accept-aging path who wish they could pursue more. We use 0.44 as that anticipatory-regret-equivalent indirect measure. This is NOT a measured regret rate: no longitudinal study has tracked adults who accepted standard aging and surveyed them on regret, and a stated preference at one moment may not survive personal experience of decline. The figure is an indirect measure only.
  2. [2] National Center for Health Statistics / CDC (Data Brief 561) — Dietary Supplement Use Among Adults: United States, August 2021-August 2023 検証済み
    Dietary Supplement Use Among Adults: United States, August 2021-August 2023
    統計値
    60.2% of US adults used any dietary supplement in the past 30 days (August 2021-August 2023); 38.7% used two or more; women 66.1% vs men 53.9%; supplement use increased with age from 46.3% (20-39) to 75.9% (60+); two-or-more use grew from 30.9% in 2013-14 to 38.7% in 2021-23
    抜粋
    “"Overall, 60.2% of adults age 20 and older took any dietary supplement. … Overall, 38.7% of adults took two or more dietary supplements. … More women age 20 and older (66.1%) than men (53.9%) took any dietary supplement. … The percentage of adults taking any dietary supplement increased with age, from 46.3% among those ages 20-39 to 60.3% among those 40-59 to 75.9% among those 60 and older. … The percentage of adults taking two or more dietary supplements increased from 2013-2014 (30.9%) through August 2021-August 2023 (38.7%)." ”
    出典データ
    2024-12-01
    アクセス日
    2026-05-30
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    CDC NCHS Data Brief 561, based on NHANES survey waves. Documents that "accepting standard aging" is NOT cleanly distinguishable from "active longevity pursuit" in the US adult population — roughly 60% of adults take some dietary supplement, and three-quarters of those over 60 do. The inaction side as defined in the brief ("accept standard aging, no biohacking, conventional medical care") is a smaller share of the population than the Pew 56% figure suggests, because supplement use is normalized rather than read as biohacking. Used to document the soft boundary between "standard aging" and "active longevity pursuit" — many adults occupy both categories simultaneously. Not a regret rate; a prevalence anchor.

注意事項

どちらの率も重度の代理指標である。作為側には直接の測定がなく、最も近いのは二つの異なる測定である。オランダの老化防御調査における長寿介入の採用への意欲の欠如(サプリメントには70%が意欲的で、ラパマイシンには約10%に低下)と、NHANES 近縁の文献で観察されたサプリメント摂取の長期的な中断である。いずれも「長寿介入を追求したことを後悔したか」の直接的な測定ではない。そのような調査は存在しない。38%という不作為側の率は、Pew 2013 で急進的な寿命延長治療を望むだろうと述べた割合であり、老化を受け入れる道にあってより多くを望むことの予期的な後悔等価であって、選好の数字であり回顧的な後悔の測定ではない。(以前の版は Pew の項目を逆転させ、寿命延長を拒む56%を不作為の「後悔」率として用いていたが、これは逆であった。標準的な老化に満足している人は、それを受け入れたことを後悔する可能性が最も低いからである。)45歳の時点で120歳まで生きたいと述べる成人は、75歳では違う感じ方をするかもしれない。この意思決定は双方向だが証拠基盤は非対称である。査読済みの RCT は一つの介入(カロリー制限、CALERIE 第2相)の心血管代謝上の便益を記録しているが、長寿を追求したか老化を受け入れたかの実体験としての後悔を記録した同等の文献はない。Bryan Johnson 型のバイオハッキングは作為側の人口のごく一部であり、縦断的な結果データなしに大きく報道されている。「標準的な健康的生活」と「積極的な長寿追求」の境界は本当に曖昧である。食事サプリメントを摂取する米国の成人の60%は、自分を長寿追求者とみなすかもしれないし、みなさないかもしれない。Pew の予期的データと老化防御への意欲のデータが利用可能な最も近い錨だが、いずれも後悔のループを閉じておらず、その結果このエントリーを proxy_only:true で公表している。どちらの側の回顧的後悔の大きさも本当に未測定である。

生データ: /api/decisions.json

このデバイスで最近見た項目